JTJan Toms

Jan Toms

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Jan Toms has a total of 38 co-authors. Here are the top co-authors by number of shared publications:

  • Petr Bradna

    12nd Department of Internal Medicine-Gastroenterology, Charles University in Prague, Medical Faculty and University Hospital in Hradec Kralove

    7 shared publications
  • T. Soukup

    II. GE department of medicine

    6 shared publications
  • Stanislav Rejchrt

    2nd Department of Internal Medicine, Charles University Teaching Hospital, Hradec Králové, Czech Republic

    5 shared publications
  • Tomáš Soukup

    Department of Histology and Embryology, Faculty of Medicine in Hradec Kralove, Charles University, Hradec Kralove, Czech Republic

    5 shared publications
  • Z. Hrncir

    2nd Department of Medicine - Division of Rheumatology, Faculty Of Medicine and University Hospital, Hradec Kralove, Czech Republic

    4 shared publications
  • Jan Bures

    Department of Medicine, 1st Faculty of Medicine, Charles University, Military University Hospital Prague, U Vojenske Nemocnice 1200, 169 02 Prague, Czech Republic

    3 shared publications

Latest Publications

  • Open Access

    Methotrexate impact on radiographic progression in biologic-treated rheumatoid arthritis under clinical remission: A case report on monozygotic Caucasian twins

    by Tomas Soukup, Jana Nekvindova, Martin Dosedel, Jindra Brtkova, Jan Toms, Drahomira Bastecka, Petr Bradna, Jiri Vlcek, Petr Pavek

    We describe Caucasian monozygotic twin brothers with rheumatoid arthritis (RA) and discuss influence of predictors to methotrexate (MTX) outcome treatment. Single nucleotide polymorphisms (SNPs) of the MTX metabolic pathways were genotyped. Twins have multiple mutations: a CC mutation of SNP 1298A>C in methylenetetrahydrofolate reductase (MTHFR) gene, CC mutations of three SNPs in the adenosine receptor gene ADORA2A (rs3761422_4217241T>C, rs2267076_4221164T>C, rs2236624_4226593T>C), and a heterozygous genotype in SNPs ATIC_rs2372536_347C>G, MTHFD1_rs2236225_1958G>A. These mutations are known to predict a worse outcome of MTX treatment. The twins had different lifestyles (alcohol drinking and smoking in Twin 1, regular coffee consumption in Twin 2), but a very similar clinical presentation of the outset of RA, radiographic scoring according to the Sharp/van der Heijde method with an almost identical antibodies presentation. The period of the patients before anti-TNFα treatment was characterized by unsuccessful per oral MTX pharmacotherapy in both cases (a low effect of MTX in Twin 1; an early discontinuation of MTX due to an adverse event in Twin 2). In both twins, the outcome of well-controlled anti-TNFα treatment (co-medication with MTX in Twin 1) for 10 years was expressed as low disease activity measured using composite index DAS28. It is interesting that Twin 2 had an unfavorable radiographic scoring after a 10-year follow-up than Twin 1 in spite of the comparable DAS28 in Twin 2 and smoking in Twin 1. In conclusion, co-medication of MTX with biologics may impact on RA radiographic progression despite predicted bad MTX outcome based on pharmacogenetic analysis.


  • Open Access

    Risk Factors of Acute Pancreatitis in Oral Double Balloon Enteroscopy

    by Marcela Kopáčová, Jan Bureš, Stanislav Rejchrt, Jaroslava Vávrová, Jolana Bártová, Tomáš Soukup, Jan Tomš, Ilja Tachecí

    Double balloon enteroscopy (DBE) was introduced 15 years ago. The complications of diagnostic DBE are rare, acute pancreatitis is most redoubtable one (incidence about 0.3%). Hyperamylasemia after DBE seems to be a rather common condition respectively. The most probable cause seems to be a mechanical straining of the pancreas. We tried to identify patients in a higher risk of acute pancreatitis after DBE. We investigated several laboratory markers before and after DBE (serum cathepsin B, lactoferrin, E-selectin, SPINK 1, procalcitonin, S100 proteins, alfa-1-antitrypsin, hs-CRP, malondialdehyde, serum and urine amylase and serum lipase). Serum amylase and lipase rose significantly with the maximum 4 hours after DBE. Serum cathepsin and procalcitonin decreased significantly 4 hours after DBE compared to healthy controls and patients values before DBE. Either serum amylase or lipase 4 hours after DBE did not correlate with any markers before DBE. There was a trend for an association between the number of push-and-pull cycles and procalcitonin and urine amylase 4 hours after DBE; between procalcitonin and alfa-1-antitrypsin, cathepsin and hs-CRP; and between E-selectin and malondialdehyde 4 hours after DBE. We found no laboratory markers determinative in advance those patients in a higher risk of acute pancreatitis after DBE.


  • AB0565 Diffuse Alveolar Hemorrhage, Diagnosis, Treatment and 3-Year Prognosis in A Group of 32 Cases of Tertiary Centre

    by P. Bradna, J. Manak, T. Soukup, J. Toms, M. Kodeda

    Objectives Diffuse alveolar hemorrhage (DAH) is severe, life-threatening syndrome, affecting the patients with systemic vasculitis and other systemic connective tissue diseases. It can be often the first manifestation of systemic disease. Frequently DAH is the acute incident, which often leads to the rapidly emerging respiratory and/or renal failure with requirement of ventilatory support and with high mortality rate. Methods Diffuse alveolar hemorrhage was diagnosed on the basis of bronchoscopy and CT examination in patients with rapidly progressive respiratory insufficiency or newly emerged hemoptysis. Artificial ventilation was started in majority of cases.Therapeutically were used high doses of steroids i.v. (1000 mg 3–5 times in the iv infusion), Cyclophosphamide pulse, and plasmapheresis in some cases. Results The group of patients consisted of 32 cases; the average age of patients was 54 years (20–71) years. In half of patients was the episode of DAH the first manifestation of the disease. 16 patients were pro3 ANCA-positive, 7 patients MPO-ANCA positive, 6 patient had known systemic connective tissue disease 46.8% of patients survive 3 years from the acute episode of DAH, including two with repeated hemorrhage. 15 patients died during the acute phase of the disease, 3 more died during next 3 years, two of them on an opportunistic infection. Steroids were used for all patients, cyclophosphamide in 71, plasmapheresis in 56%, and i.v. immunoglobulins for 6.25 percent of patients. Patients who survive 3 years after the acute episode, had significantly lower necessity of artificial ventilation (40 vs. 93%) against the fatal cases, unfavorable prognostic sign was long term connective tissue disease. Residual lung impairment is present in 53% of the surviving patients; the signs of pulmonary arterial hypertension are present in 20% of the surviving group. Conclusions Diffuse alveolar hemorrhage is a sudden life-threatening event with a high mortality rate (46%) in the acute phase and during the first 3 years after the acute episode (20% of survivors). Up to half of patients the episode of DAH may be the first manifestation of the disease. Survival of patient depends on rapid diagnosis and the initiation of intensive immunosuppressive therapy. Respiratory failure is the major negative quoad vitam prognostic factor. Suspect the diffuse alveolar bleeding is necessary always in the case of a rapidly progressive respiratory failure. Acute bronchoscopy and x-ray examination give diagnosis of DAH, which further specify the acute examination of ANCA antibodies (71% of the report was ANCA antibodies positive. Disclosure of Interest None declared


    • 29 January 2015
      • Vol. 33  (3) , 426-32

    Genetic polymorphisms in metabolic pathways of leflunomide in the treatment of rheumatoid arthritis.

    by Tomáš Soukup, Martin Dosedel, Jana Nekvindova, Jan Toms, Jiri Vlcek, Petr Pavek

    Leflunomide (LEF) is a disease-modifying anti-rheumatic drug used for treating rheumatoid arthritis (RA). More than 50% of patients are withdrawn from LEF treatment within one year, mainly due to AEs. Importantly, it is not possible to predict which patients will respond to LEF therapy nor if adverse outcome occurs. Pharmacogenetic studies indicate an impact of single nucleotid polymorphisms (SNPs) on the variability in LEF serum levels with potential relevance to effectiveness and tolerability in individual RA patients. In vitro studies have demonstrated that cytochromes P450 (CYPs), mainly CYP1A2, CYP2C19, and CYP3A4, are involved in LEF metabolite activation. It was shown that CYP1A2*1F allele may be associated with LEF toxicity in patients with RA. In case of dihydroorotate dehydrogenase (DHODH) gene SNP (rs3213422, 19C>A), it was shown that C allele may be associated with LEF toxicity and therapeutic effect. Finally, oestrogen receptor genes SNPs in females may be associated with LEF therapy efficacy. In summary, the results of the current studies suggest a possible diagnostic value of genotyping for patients with RA as biomarkers of LEF therapy efficacy or conversely as indicators of serious side effects. In the future, it will be necessary to corroborate these results in studies with larger numbers of patients and longer follow-up. Moreover, it would be appropriate to focus on CYP2C19, ATP5A1 and PKD1L3 genes.


  • THU0315 Increasing Proportion of Concomitant Fibromyalgia in Rheumatoid Arthritis Cohort Corresponds to Growing Arthritis Activity Assessed by Composite Indices

    by J. Toms, T. Soukup, M. Tosovsky, P. Bradna, Z. Hrncir

    Background Fibromyalgia (FM) is well described as a concomitant syndrome that can frequently accompany connective tissue diseases, especially rheumatoid arthritis (RA). In this epoch of modern biologic therapy and RA tight control effort it is essential to count various factors that can impact RA activity or modulate activity assessment. Objectives To compare proportional representation of FM in RA patients cohort according to increasing arthritis activity assessed by composite indices in a regional, monocentric, cross-sectional study. Methods Examination of 120 consecutive patients (pts) with RA was performed in the terciary outpatient rheumatology department. Diagnosis of concomitant FM was established according to ACR criteria (1990). Standard Manual Tender Point Survey was used for the examination of FM tender points. The following data were recorded: demographic data, tender point count (TPC), Fibromyalgia Impact Questionnarie (FIQ) score and RA activity composite indices (DAS-28, CDAI, SDAI). Short Form 36 items (SF-36) and Health Assessment Questionnaire (HAQ) were used for evaluation of quality of life (QOL) and functional disability, respectively. Statistical analysis was based on Student's t-test or Fisher exact test (statistical significance level 0.05). Results Concomitant FM was diagnosed in 25 (20.8%) pts with RA, 4 men and 21 women. Comparing RA without FM (RAF-) and with FM (RAF+), there were no significant differencies in sociodemographic characteristics, laboratory inflammatory markers, RF and ACPA seropositivity. RAF+ pts in comparison to RAF- pts reached significantly higher scores of RA activity (DAS-28 5.35±1.1 vs. 3.67±1.4, pConclusions Concomitant fibromyalgia appears frequently in RA pts and has significant impact on the disease activity assessment and disability level because of altered pain perception. Patients with high disease activity measured by widely used composite indices are usually indicated for more intensive immunosuppressive or biologic therapy. But in this case it is necessary to realize this group contains higher portion of FM pts resulting in risk of wrong therapy reinforcement. Disclosure of Interest : None declared DOI 10.1136/annrheumdis-2014-eular.5942

  • AB0591 Acute Respiratory Failure – the Reason for Urgent Rheumatologic Examination?

    by P. Bradna, J. Manak, V. Koblizek, T. Soukup, J. Toms, M. Tosovsky, M. Kodeda, D.H. Nikolov

    Background Acute respiratory failure is a reason for urgent admission to ICU. Statistical data show, that about 10 percent of deaths of respiratory failure patients on ICU is caused by diffuse alveolar hemorrhage syndrome (DAH). Barring infection, coagulation defects or oncological therapy complications, systemic connective tissue diseases must be considered as a reason. Less frequently there are patients with known systemic disease, more frequently DAH is the first manifestation of connective tissue disease, especially systemic vasculitis or SLE. Methods During 8 years 24 cases of diffuse alveolar hemorrhage in rheumatologic diseases were treated, 22 on ICU. 21 of them needed artificial ventilation. We observed the symptoms of preceded systemic disease, autoantibodies in time of DAH, hospital mortality and follow up of patients. Results 13 women and 11 men were affected, average age was 52,6 (21-74) years. Only in 32% of them had known diagnosis of systemic connective tissue disease before episode of alveolar hemorrhage. Diagnose of DAH was assessed by bronchoscopy with examination of bronchoalveolar lavage fluid and X-ray or CT results. 21 patients needed artificial ventilation.Most frequent immunological feature was ANCA antibody in 75% of our group. Proteinase -3 specificity was present in 58%, myeloperoxidase in 16% of our patients. ANA antibodies were founded in 21% of our patients, in one patient there was atypical anti GBM antibodies.Antiphospholipid antibodies were not present. Negative results had 20,8% of our group. Patients were treated by pulse methylprednisolone therapy, plasmapheresis, and i.v. Cyclophosphamide or i.v. immunoglobulins in cases where immunosuppressive therapy was contraindicated. Hospital mortality was 42 percent (10 patients). 14 patients are followed on outpatient base, in 3 of them chronic hemodialysis for irreversible renal failure is necessary, Early diagnosis and start of intensive immunomodulating therapy were one of crucial factors for survival of this life-threatening complication, however intensive immunosuppression is high-risky in patients with artificial ventilation support. Conclusions Diffuse alveolar hemorrhage is one of the important reasons of acute respiratory failure. In significant part of such patients the systemic connective tissue disease, mostly systemic vasculitis, is the cause of complication. Serious episode of DAH may be the first manifestation of rheumatologic disease. Bronchoscopic examination for DAH may be performed as early as possible, therefore early start of immunosuppressive therapy is crucial for survival of such patients. Outside of bronchoscopy instant assessment of ANCA antibodies is helpful. References West S, Arulkumaran N, Ind PW, Pusey CD Diffuse alveolar haemorrhage in ANCA-associated vasculitis. Intern Med. 2013;52(1):5-13. Acknowledgements Supported by MH CZ - DRO (UHHK, 00179906) Disclosure of Interest None declared DOI 10.1136/annrheumdis-2014-eular.4884

  • Tu1150 Laboratory Predictors of Hyperamylasemia and Hyperlipasemia After Double Balloon Enteroscopy

    by Marcela Kopacova, Jan Bures, Stanislav Rejchrt, Jaroslava Vavrova, Tomas Soukup, Jan Toms, Jolana Bartova, Ilja Tacheci


  • Open Access

    Cylindrical battery ingested by a 1-year-old baby – does the voltage matter?

    by Jiri Cyrany, Jan Melek, Petr Dedek, Jan Toms, Stanislav Rejchrt

    The ingestion of a button-type battery cell by a child is an indication for urgent extraction (within 2 hours) if it has impacted in the esophagus because of the risks of major or even fatal complications, such as perforation and bleeding. In contrast, the ingestion of a cylindrical-type battery that passes into the stomach is not an indication for acute extraction as long as it is not causing symptoms. A follow-up radiograph after a 4-day interval is considered to be sufficient [1] [2]. We were asked to extract a cylindrical battery from the stomach of a 12-month-old asymptomatic girl approximately 26 hours after she had been witnessed ingesting it ([Fig. 1]). The procedure was performed with the patient under general anesthesia, using a gastroscope (GIF Q180; Olympus Optical Co., Tokyo, Japan) with a polypectomy snare. During the endoscopy, two ulcers, approximately 10 – 15 mm in diameter, were found on the front and back walls of the stomach ([Fig. 2]), together with several small erosions on the greater curvature ([Video 1]). The battery was identified as a type A23. A proton pump inhibitor was prescribed and ampicillin/sulbactam was added for complicating nasopharyngitis; otherwise the child’s subsequent course was uneventful. The supposed mechanism of battery-induced injury consists of (in order of importance): generation of an external electrolytic current that hydrolyses tissue fluids and produces hydroxide at the negative pole; leakage of alkaline electrolyte; and physical pressure [3]. A type-A23 battery consists of eight button alkaline cells (based on a manganese dioxide chemical system) bound together to form a cylinder that is 10 mm in diameter and 28 mm long and gives off a voltage as high as 12 V, as opposed to 1.5 V in more common and similar sized microbatteries (type AAA; 10 × 44 mm) [4]. We propose that in terms of the indication and timing of an endoscopic extraction of a cylindrical battery ingested by a child, the particular type and voltage of the battery should be considered, with particular regard being paid to the higher voltage types, such as A23 or A27. Potentially dangerous gastrointestinal tract damage could therefore be prevented. Endoscopy_UCTN_Code_CCL_1AB_2AF


  • Open Access

    Whipple’s Disease: Our Own Experience and Review of the Literature

    by Jan Bureš, Marcela Kopáčová, Tomáš Douda, Jolana Bártová, Jan Tomš, Stanislav Rejchrt, Ilja Tachecí

    Whipple’s disease is a chronic infectious systemic disease caused by the bacterium Tropheryma whipplei. Nondeforming arthritis is frequently an initial complaint. Gastrointestinal and general symptoms include marked diarrhoea (with serious malabsorption), abdominal pain, prominent weight loss, and low-grade fever. Possible neurologic symptoms (up to 20%) might be associated with worse prognosis. Diagnosis is based on the clinical picture and small intestinal histology revealing foamy macrophages containing periodic-acid-Schiff- (PAS-) positive material. Long-term (up to one year) antibiotic therapy provides a favourable outcome in the vast majority of cases. This paper provides review of the literature and an analysis of our 5 patients recorded within a 20-year period at a tertiary gastroenterology centre. Patients were treated using i.v. penicillin G or amoxicillin-clavulanic acid


  • AB0251 Small intestine enteropathy in patients with rheumatoid arthritis and osteoarthritis.

    by P. Bradna, I. Tacheci, S. Rejchrt, T. Soukup, J. Toms, D. Bastecka, J. Bures

    Background Involvement of small intestine is demonstrable up to 72% of patients, using non-steroidal antirheumatic drugs (NSAIDs). Quite little is known about influence of principal diagnosis on incidence and severity of enteropathy. Objectives Aim of our study was to compare small bowel enteropathy in rheumatoid arthritis and osteoarthritis patients. Methods Capsule endoscopy is currently the leading method for non-invasive diagnostics of small bowel lesions. This method is safe, reproducible, with high diagnostic yield, discriminating extend localization, severity and character of lesions. We examined 37 rheumatoid arthritis (RA) patients and 14 patients, using NSAIDs on a regular basis for osteoarthritis (OA). Group of 13 healthy persons not using NSAIDs served as a control group. We excluded people with comorbidities potentially involving the bowel or leading to a blood loss. We evaluated extend, severity and localizations of lesions. Qualitative data were evaluated by Fisher’s exact test, Armitage test or chi2 test, quantitative data were evaluated by Student’s T-test or Mann Whitney test in case of nonparametric distribution Results We demonstrated enteropathy in 67.5% of rheumatoid arthritis patients, moderate or severe lesions in 20% of RA patients. In osteoarthritis group there was 42.9% patients with enteropathy, severe in 7% of them. In control group there was demonstrated only mild changes in 15% people. Moderate or severe lesions were not demonstrating in NSAIDs non-users. Lesions were equally frequent in ileum and jejunum, duodenum was involved rarely. The same distribution was demonstrated also in moderate and severe lesions. Conclusions Rheumatoid arthritis patients, using non-steroidal antirheumatic drugs have significantly more frequent and more severe lesions of small bowel then osteoarthritis NSAIDs users. Jejunum and ileum were involved with equal frequency and severity, duodenal involvement was rare. Next studies must reply, if differences are caused by genetic predisposition, co medication, or they are caused by direct impact of rheumatoid arthritis. Disclosure of Interest None Declared